“Possibilities of early prevention of chronic kidney disease in patients with type 2 diabetes mellitus based on clinical and anamnestic data”

Authors

  • Kholikov A.Yu Republican Specialized Scientific and Practical Medical Center of Endocrinology of the Ministry of Health of the Republic of Uzbekistan named after academician
  • Begmatov B.B Health of the Republic of Uzbekistan named after academician. E.Kh. Turakulov, hemodialysis department
  • Urmanova Yu.M Health of the Republic of Uzbekistan named after academician. E.Kh. Turakulov, hemodialysis department
  • Narziev V.Sh Tashkent Pediatric Medical Institute, Department of Endocrinology, Pediatric Endocrinology

DOI:

https://doi.org/10.62480/tjms.2024.vol29.pp43-50

Keywords:

anamnestic, possibilities, CKD

Abstract

to study the possibilities of early prevention of CKD in patients with type 2 diabetes based on clinical and anamnestic data.

References

Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997;157:1413–18.

Fuller JH, Stevens LK, Wang SL, et al. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(suppl 2):S54–64.

Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32.

de Boer IH, Rue TC, Hall YN. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532–9.doi:10.1001/jama.2011.861

Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-.doi:10.1056/NEJMoa1310799pmid:http://www.ncbi.nlm.nih.gov/pubmed/24738668

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.doi:10.1016/j.diabres.2009.10.007

Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016;12:73-81.doi:10.1038/nrneph.2015.173

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98:S1-115.doi:10.1016/j.kint.2020.06.019pmid:http://www.ncbi.nlm.nih.gov/pubmed/32998798

American Diabetes Association. 11. microvascular complications and foot care: standards of medical care in Diabetes-2021. Diabetes Care 2021;44:S151-67.doi:10.2337/dc21-S011pmid:http://www.ncbi.nlm.nih.gov/pubmed/33298422

Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.doi:10.1056/NEJMoa0806470

Schernthaner G, Schernthaner-Reiter MH. Therapy: risk of metformin use in patients with T2DM and advanced CKD. Nat Rev Endocrinol 2015;11:697-9.doi:10.1038/nrendo.2015.132pmid:http://www.ncbi.nlm.nih.gov/pubmed/26284445

Kwon S, Kim YC, Park JY, et al. The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care 2020;43:948–55.doi:10.2337/dc19-0936pmid:http://www.ncbi.nlm.nih.gov/pubmed/32132005

Roumie CL, Chipman J, Min JY, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA 2019;322:1167-77.doi:10.1001/jama.2019.13206pmid:http://www.ncbi.nlm.nih.gov/pubmed/31536102

Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9.doi:10.1001/archinternmed.2010.409pmid:http://www.ncbi.nlm.nih.gov/pubmed/21098347

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.doi:10.1056/NEJMoa1515920

Wanner C, Inzucchi SE, Zinman B, et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG outcome trial. Diabetes Obes Metab 2020;22:2335-47.doi:10.1111/dom.14158pmid:http://www.ncbi.nlm.nih.gov/pubmed/32744354

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.doi:10.1056/NEJMoa1812389pmid:http://www.ncbi.nlm.nih.gov/pubmed/30415602

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.doi:10.1056/NEJMoa1811744

Downloads

Published

2024-02-14

Issue

Vol. 29 (2024): TJMS

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

User Rights

Under the Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC), the author (s) and users are free to share (copy, distribute and transmit the contribution).

Rights of Authors

Authors retain the following rights:
1. Copyright and other proprietary rights relating to the article, such as patent rights,
2. the right to use the substance of the article in future works, including lectures and books,
3. the right to reproduce the article for own purposes, provided the copies are not offered for sale,
4. the right to self-archive the article.

How to Cite

“Possibilities of early prevention of chronic kidney disease in patients with type 2 diabetes mellitus based on clinical and anamnestic data”. (2024). Texas Journal of Medical Science, 29, 43-50. https://doi.org/10.62480/tjms.2024.vol29.pp43-50